Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843073 | 0.81 | — | — | |
| SCHEMBL449290 | 0.81 | ALDH1A1 (0.31) | ELANEPRKCA | |
| SCHEMBL6921711 | 0.80 | PRKCA (0.36) | ELANEPRKCA | |
| SCHEMBL7515876 | 0.78 | — | — | |
| SCHEMBL3269571 | 0.78 | FAAH (0.32) | — | |
| SCHEMBL451530 | 0.78 | TSHR (0.36) | PRKCA | |
| SCHEMBL4156482 | 0.76 | PRKCA (0.31) | ELANEPRKCA | |
| SCHEMBL16943710 | 0.76 | ALDH1A1 (0.33) | ELANEPRKCA | |
| SCHEMBL2438346 | 0.76 | ALDH1A1 (0.33) | ELANEPRKCA | |
| SCHEMBL2438349 | 0.76 | ALDH1A1 (0.33) | ELANEPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-4898939-A | Process for preparing 2β-substituted-methylpenicillin derivatives | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1990-02-06 | — | — | US | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| US-4614819-A | REACTING A THIOL ESTER COMPOUND WITH 7-AMINOCEPHALOSPORIN IN PRESENCE OF BORON TRIFLUORIDE | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-09-30 | — | — | US | disclosed |
| US-4610983-A | N-acyl acidic amino acid diamide derivative, a salt thereof, and an anti-ulcer agent containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| EP-0097446-B1 | PENICILLIN DERIVATIVES AND PROCESS FOR PREPARATION OF THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1986-02-26 | — | — | EP | disclosed |
| US-4562073-A | BETA-LACTAMASE INHIBITORS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-12-31 | — | — | US | disclosed |
| EP-0138523-A1 | Penicillin derivatives and process for preparing the same (11111) | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-04-24 | — | — | EP | disclosed |
| US-4507239-A | B-LACTMASE INHIBITORY ACTION | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-03-26 | — | — | US | disclosed |
| US-4496484-A | Penicillin derivatives | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-01-29 | — | — | US | disclosed |
| US-4489072-A | BACTERICIDE, ANTIBIOTIC | TOYAMA CHEMICAL CO., LTD. (JP) | 1984-12-18 | — | — | US | disclosed |
| EP-0097446-A1 | Penicillin derivatives and process for preparation of the same | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1984-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | ELANE 2900/4885PRKCA 4822/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | ELANE 306/4885PRKCA 4753/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | ELANE 3244/4885PRKCA 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.